


Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1 (Original) A compound of formula I:



where n is 2, 3 or 4;

Ar¹ represents phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, C₁₋₄alkoxy or C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy;

Ar² represents phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, C₁₋₄alkoxy or C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy;


R¹ represents C₁₋₄alkyl, or together with R² completes a pyrrolidine, piperidine or homopiperidine ring;

R² represents H or C₁₋₆alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy; or together with R¹ completes a pyrrolidine, piperidine or homopiperidine ring; or together with R³ completes a tetrahydroisothiazole-1,1-dioxide ring; and

R³ represents phenyl, naphthyl or heteroaryl, any of which may bear up to 3 substituents selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₂₋₆acyl, C₂₋₆acyloxy, C₂₋₆acylamino, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino or C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy; or R³ represents CF₃ or a non-aromatic hydrocarbon group of up to 6 carbon atoms optionally bearing one substituent selected from halogen, CN, CF₃, OH, OCF₃, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₂₋₆acyl, C₂₋₆acyloxy, C₂₋₆acylamino, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino or phenyl, naphthyl or heteroaryl, any of which may bear up to 3 substituents selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₂₋₆acyl, C₂₋₆acyloxy, C₂₋₆acylamino, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino or C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy; or R³ together with R² completes a tetrahydroisothiazole-1,1-dioxide ring;

or a pharmaceutically acceptable salt thereof.

Claim 2 (Original) A compound according to claim 1 of formula II:




II

where n , Ar^1 , Ar^2 , R^2 and R^3 are as defined in claim 1;

or a pharmaceutically acceptable salt thereof.

Claim 3 (Original) A compound according to claim 1 of formula III:



III

wherein m is 1, 2 or 3;

R^{3a} represents R^3 which does not form a ring with R^2 ;

and Ar^1 , Ar^2 and R^3 are as defined in claim 1;

or a pharmaceutically acceptable salt thereof.


Claim 4 (Amended) A compound according to ~~any previous claim 1~~ wherein Ar^1 is 4-chlorophenyl or 4-trifluoromethylphenyl and Ar^2 is 2,5-difluorophenyl.

Claim 5 (Amended) A pharmaceutical composition comprising a compound according to ~~any previous claim 1~~, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claims 6-7 (Canceled)

Claim 8 (Amended) A method of treatment of a subject suffering from or prone to a condition associated with the deposition of β -amyloid which comprises administering to that subject an effective amount of a compound according to ~~any of claims 1-4~~ claim 1 or a pharmaceutically acceptable salt thereof.


Claim 9 (Original) A method of preparing a compound according to claim 1 in which R^2 does not form a ring with R^3 comprising reaction of an amine (IV) with R^{3a} -SO₂Cl:



where R^{2a} represents R² which does not complete a ring with R³,

R^{3a} represents R³ which does not complete a ring with R², and n, Ar¹, Ar², R¹, R² and R³ are as defined in claim 1.

Claim 10 (Original) A method of preparing a compound according to claim 1 in which R² and R³ together complete a tetrahydroisothiazole-1,1-dioxide comprising reaction of an amine:



where n, Ar¹, Ar² and R¹ are as defined in claim 1, with L-(CH₂)₃-SO₂Cl where L represents a leaving group, followed by intramolecular alkylation of the resulting sulphonamide nitrogen.